K V Pharma CL A News - KVA

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

ST. LOUIS, Dec. 15 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that on December 10, 2009, the Company...

KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet

ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that that it has entered into an employment...

KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments

ST. LOUIS, Nov. 13 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that IVS Associates, Inc., the inspector...

Large Generic Drug Cos Benefiting From Price Stability

Quality control issues and shortages at several smaller generic drug makers have brought increased price stability for the larger players in the...

KV Pharmaceutical Divests ANDA for Generic Version of Duac(R)

ST. LOUIS, Sept. 21 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced the sale to Perrigo Company (NASDAQ:PRGO...

KV Pharmaceutical Receives Stockholder Action by Written Consent

ST. LOUIS, Sept. 15 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that on September 14, 2009, the Company...

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

ST. LOUIS, Sept. 9 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that on August 31, 2009, the Company...

KV Pharmaceutical Appoints Interim Chief Financial Officer

ST. LOUIS, Sept, 4 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that on September 2, 2009, Thomas McHugh...

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

ST. LOUIS, Aug. 7 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) (the "Company") today announced that the Company notified...

UPDATE: Watson Pharma 2Q Net Down 12%; Toprol Seen Boosting Fiscal Year

Watson Pharmaceuticals Inc. (WPI) reported a 12% drop in second-quarter earnings, due to items, but raised its 2009 financial expectations citing...

KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K

ST. LOUIS, June 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) (the "Company") today announced that it received a letter...

KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter

ST. LOUIS and BUDAPEST, Hungary, June 18 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE:KVa/KVb) today announced that it has entered...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

K V Pharma CL A (KVA)

Professional-Grade Tools, for Individual Investors.

KVA News

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet

KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments

Large Generic Drug Cos Benefiting From Price Stability

KV Pharmaceutical Divests ANDA for Generic Version of Duac(R)

KV Pharmaceutical Receives Stockholder Action by Written Consent

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

KV Pharmaceutical Appoints Interim Chief Financial Officer

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

UPDATE: Watson Pharma 2Q Net Down 12%; Toprol Seen Boosting Fiscal Year

KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K

KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter

KVA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

K V Pharma CL A (KVA) News

K V Pharma CL A (KVA)

Professional-Grade Tools, for Individual Investors.

KVA News

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet

KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes To Approve Bylaw Amendments

Large Generic Drug Cos Benefiting From Price Stability

KV Pharmaceutical Divests ANDA for Generic Version of Duac(R)

KV Pharmaceutical Receives Stockholder Action by Written Consent

KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent

KV Pharmaceutical Appoints Interim Chief Financial Officer

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

UPDATE: Watson Pharma 2Q Net Down 12%; Toprol Seen Boosting Fiscal Year

KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K

KV Pharmaceutical Forms Licensing Partnership with Gedeon Richter

KVA Discussion

Your Recent History